NCT05806359View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Danicamtiv

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05806359 - A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants | Biotech Hunter | Biotech Hunter